Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction

Indian Journal of Cancer

Volumn 43, Issue 1, 2006, Pages 16-19

  Sharma, Atul ^a   Raina, V ^a   Lokeshwar, N ^a   Deo, S V S ^a   Shukla, N K ^a   Mohanti, B K ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Cisplatin; Etoposide; Gastric; Gastroesophageal; Paclitaxel

Indexed keywords

EID: 33745151412     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.25770     Document Type: Article

References (12)

1. Kohne CH, Wils JA, Wilke HJ. Development in the treatment of gastric cancer in Europe. Oncology (Huntingt) 2000;14;22-5.
2. Cocconi G, DeLisi V, DiBlaso B. randomized comparison of 5 FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263.
3. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Crook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985;253:2061-7.
4. Gastrointestinal Tumor Study Group. Trianzinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin:results of a three-arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst 1988;80:1011.
5. Elliot TE, Moertel CG, Wieand HS, Hahn RG, Gerstner JB, Tschetter LK, et al. A phase II study of the combination of cispaltin and etoposide in the therapy of advanced gastric cancer. Cancer 1990;65;1491.
6. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. a phase III randomized study of 5 fluorouracil and cisplatin versus 5 fluorouracil, doxorubicin and mitomycin C versus 5 fluouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
7. Wils J, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer- A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
8. Cocconi G, Bella M, Zironi S, Algeri R, DiCostanzo F, DeLisi V, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 1994;12:2687.
9. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF, et al. phase li study of Taxol in patients with advanced gastric cancer. Cancer J Sci Am 1998;4:269-74.
10. Lokich JJ, Sonneborn IT, Anderson NR, Bern MM, Coco EV, Dow E, et al. combined Paclitaxel, Cisplatin and Etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999;85:2347-51.
11. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, et al. Cisplatin, epirubicin, leucoverine and 5-fluourouracil (PELF) is more active than 5-fluourouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003;14:1258-63.
12. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5 fluorouracil compare to cisplatin © and 5 fluorouracil (F) for chemotherapy naïve patients with metastatic or locally recurrent, unresectable gastric cancer (MGC):Interim results of a randomized phase III trial (V 325). Proc Am Soc Clin Oncol 2003;22:249(abstr 999).